Logo for Cellectis S.A.

Cellectis Investor Relations Material

Latest events

Logo for Cellectis S.A.

Q4 2024

Cellectis
Logo for Cellectis

Q1 2025

12 May, 2025
Logo for Cellectis

Q4 2024

14 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies

Latest reports from Cellectis S.A.

Access all reports
Cellectis is a clinical stage biotechnological company, developing immuno-oncology products based on gene-edited T-cells. According to Cellectis, it is one of the very few companies capable of generating next generation T-cell product candidates in an entirely novel approach. By combining the full functionality of T-cells with the specificity provided by artificial antigen receptors (chimeric antigen receptors), their program aims at achieving superior antiviral, anti-tumor and anti-inflammatory potential.